Bachem Holding (BANB) Fair Value & Analysis
Healthcare · CH · Market cap CHF 5.8B
Fair value as of: Jun 24, 2026
From 16 valuation models · updated 6 days ago
Share price −1.6% over the past month.
Price vs Fair Value (12 months)
12‑month range CHF 43.33 – CHF 73.25 · fair‑value band CHF 20.56 – CHF 34.74 · the CHF 67.70 price screens above the CHF 27.72 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Bachem Holding (BANB) currently trades at CHF 67.70, while our model-based Fair Value estimate is CHF 27.72 — implying the stock looks roughly 59.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Bachem Holding generated revenue of CHF 695M at a net margin of 21.4%. Revenue grew 4.7% year over year. It earns a return on equity of 10.4%. Net debt stands at CHF 26.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bachem Holding reported revenue of CHF 695M in FY2025 versus CHF 503M in FY2021, a compound +8.4%/yr. Reported net income was CHF 149M in FY2025, compounding +6.7%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bachem Holding (BANB) undervalued?
What is the fair value of BANB?
What is the quality score of BANB?
What is the revenue of Bachem Holding (BANB)?
What is the net profit margin of BANB?
Does Bachem Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.